[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343121-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343121-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","regulatory-role-of-cd39-and-cd73-in-tumor-immunity-review","Regulatory role of CD39 and CD73 in tumor immunity - Review","","Review examining how CD39 and CD73 regulate tumor immunity by controlling the ATP-to-adenosine pathway in the tumor microenvironment. CD39, also known as ENTPD1, converts extracellular ATP to ADP and AMP, and together with CD73 drives accumulation of immunosuppressive adenosine that can inhibit antitumor T-lymphocytes, reshape antigen presentation, and support malignant progression. Summarizes mechanisms, biomarker links, and therapeutic approaches targeting CD39/CD73, including evidence from multiple cancer types and clinical trials.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/regulatory-role-of-cd39-and-cd73-in-tumor-immunity-review/343121/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/regulatory-role-of-cd39-and-cd73-in-tumor-immunity-review/343121.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does CD39 do in the tumor microenvironment?","Question",{"text":63,"@type":64},"CD39 is the rate-limiting enzyme that converts extracellular ATP into ADP and AMP, which leads to accumulation of immunosuppressive adenosine in the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do CD39 and CD73 work together to shape tumor immunity?",{"text":68,"@type":64},"Together they promote conversion of ATP to adenosine, shifting the balance toward immunosuppression. Extracellular adenosine inhibits antitumor T-lymphocytes and supports malignant immune evasion.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic strategies target CD39 and CD73?",{"text":72,"@type":64},"The review discusses CD39/CD73-targeting therapeutics, including products such as monoclonal antibodies and nucleotide analogues that disrupt CD39 enzymatic activity and are being tested in early clinical settings.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343121,1790211354,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review  \nRegulatory role of CD39 and CD73 in tumor immunity  \nNicole Kaplinsky1, Kada Williams1, Dean Watkins1, Molly Adams1, Laura Stanbery2 & John Nemunaitis*,2  \n1 University of Toledo College of Medicine, Toledo, OH 43614, USA  \n2 Gradalis, Inc, Dallas, TX 75006, USA  \n*Author for correspondence: Tel.: +1 (214) 442 8100; [johnnemunaitis@gmail.com](johnnemunaitis@gmail.com)  \nCD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP) . In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.  \nFirst draft submitted: 12 October 2023; Accepted for publication: 7 March 2024; Published online:  \n23 April 2024  \nKeywords: adenosine pathway • antigen • CD39 • CD73 • ENTPD1 • immunotherapy • tumor microenvironment  \nImmune checkpoint inhibitors have revolutionized oncology care over the last 10 years. However, while robust and durable responses have been demonstrated, a large subset of patients do not respond, and most of those who doin time demonstrate recurrent disease. Signiﬁcant effort has been undertaken to identify mechanisms of immune resistance, biomarkers of response and additional immune response-modulating targets to improve therapeutic beneﬁt.  \nRecently, CD39 has been identiﬁed as a critical immune-related target [1] . CD39, also known as ENTPD1, converts extracellular adenosine triphosphate (eATP) to adenosine (ADO) . Increased ATP levels in the tumor microenvironment (TME) are associated with proinﬂammatory activity and ADO increases are anti-inﬂammatory. The balance of ATP andADO in the TME guides the cancer immune response to immune therapy [2] . Other molecular signals, notably CD73, are also involved in this process. eATP is released by stressed, injured or dying cells and in response to hypoxic conditions of the intratumor microenvironment [1,3–5] . Extracellular ADO (eADO) is a known inhibitor of antitumor T-lymphocytes, which is highlighted by frequent overexpression of CD39 on the surface of malignant cells [6–8]. Given that CD39 plays such a critical role in the immunosuppressive ADO signaling network of cancer protection, there has been robust activity exploring therapeutic modulation of CD39 and CD73 expression and activity.  \nOverexpression of CD73 is seen in hypoxic conditions and enables a greater migration of individual tumor cells [5,9–17] . The neoplastic axis of CD39/CD73 can be summarized as such: ATP is released in the TME and quickly converted to ADO, which directly promotes cancer cell growth by enhancing the invasive and metastatic properties of the cells [13] . Among these is the engagement of ADO receptors on endothelial cells that enhances the production of proangiogenic factors such as VEGF, IL-8 and b-FGF [14] . In addition to enhancing the metastatic properties of tumor cells, CD39/CD73 activation also creates an immunosuppressive effect on macrophages, neutrophils, dendritic cells and T cells [11] . Both scenarios enhance the progression of malignant disease thereby supporting research exploring CD39/CD73 as biomarkers potentially related to clinical beneﬁt and resistance [18] . More research into the correlation between CD39 expression and potential clinical biomarkers is needed, as expression and activation of CD39 also increase on all T-cell subsets associated with age [19]. In addition, there may  \n10. 2217/fon-2023-0871  2024 Gradalis, Inc. Future Oncol. (2024) 20(19), 1367–1380 ISSN 1479-6694 1367  \nReview Kaplins","cbCainMfdxHNG6CP","https://ap.wps.com/l/cbCainMfdxHNG6CP","pdf",2236547,14,"English","# Overview\n## ATP-to-adenosine signaling in the tumor microenvironment\n## Effects on immune cells and antigen presentation\n## Therapeutic targeting of CD39 and CD73\n# Mechanistic links to cancer progression\n## CD39/CD73 effects in solid tumors\n## Prognosis, immune evasion, and biomarkers\n## Genotype and expression relationships\n# Enzyme and pathway details","[{\"question\":\"What does CD39 do in the tumor microenvironment?\",\"answer\":\"CD39 is the rate-limiting enzyme that converts extracellular ATP into ADP and AMP, which leads to accumulation of immunosuppressive adenosine in the tumor microenvironment.\"},{\"question\":\"How do CD39 and CD73 work together to shape tumor immunity?\",\"answer\":\"Together they promote conversion of ATP to adenosine, shifting the balance toward immunosuppression. Extracellular adenosine inhibits antitumor T-lymphocytes and supports malignant immune evasion.\"},{\"question\":\"What therapeutic strategies target CD39 and CD73?\",\"answer\":\"The review discusses CD39/CD73-targeting therapeutics, including products such as monoclonal antibodies and nucleotide analogues that disrupt CD39 enzymatic activity and are being tested in early clinical settings.\"}]","Regulatory role of CD39 and CD73 in tumor immunity - Review | PDF",1790049982,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb5dcfe19c72ac4fef5813007fda36a3.webp",983,1322,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4eb1bcfe6c066376bf06b4fcd3a57654.webp",982,1321,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/661ed0ac41475dd7ec14996db87be042.webp",981,1319,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8acda4c89818c6d2d9b4124a1b9c04dc.webp",980,1318]